

Avexa Limited ABN 53 108 150 750 Suite 8, Level 1 61-63 Camberwell Rd Hawthorn East Melbourne 3123 Telephone +61 3 8888 1040 Facsimile +61 3 8888 1049 Website www.avexa.com.au

ASX Announcement

For immediate release

TALI efficacy trial findings published in highly regarded international journal

Melbourne, Australia, Monday 2 May 2016

Avexa Limited (Avexa, ASX: AVX) is pleased to announce that the findings from the first trial on the efficacy of the TALI program have been accepted for publication in the highly regarded *Journal of Child Psychology and Psychiatry*.

The publication entitled Computerised attention training for children with intellectual and developmental disabilities: A randomised controlled trial was produced by Avexa's Chief Research Officer, Dr Hannah Kirk.

This publication also features in Dr Kirk's PhD thesis which was rated as "exceptional" by a Cambridge University academic review. This is the highest achievable PhD merit and indicates that Dr Kirk's work is at the forefront of international doctorates in the field.

Executive Chairman, Iain Kirkwood said "we congratulate Hannah on this fantastic achievement where fewer than 5% of individuals worldwide receive this ranking. Needless to say we are delighted to have Hannah as part of the Avexa team. Her knowledge in the field of cognitive training will ensure that the TALI technology is developed on strong scientific foundations and appropriately validated through research trials."

Chief Research Officer, Dr Hannah Kirk said "as part of the Avexa team, my aim is to design scientifically driven tasks that benefit cognition and behavior in both typically developing children and clinical population, such as individuals with developmental disabilities."

END

For more information:

Iain Kirkwood Executive Chairman M: +61 408 473 496 Avexa: +61 3 8888 1040 Dr Hannah Kirk Chief Research Officer M: +61 401 199 049

www.avexa.com.au